144 - Scientific Plenary
High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: a Gynecologic Oncology Group (GOG) study
Tuesday, March 25, 2014: 11:29 AM
Ballroom B/C (Tampa Convention Center)
K. S. Tewari1, M. Sill2, D. H. Moore3, H. J. Long4, R. T. Penson5, H. Huang2, L. M. Landrum6, A. Oaknin7, H. Michael8, B. J. Monk9, L. M. Ramondetta10, T. J. Reid11 and M. M. Leitao12
1University of California at Irvine, Irvine, CA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Franciscan Physician Network Gynecologic Oncology Specialists, Indianapolis, IN, 4Mayo Clinic, Rochester, MN, 5Massachusetts General Hospital/Harvard University, Boston, MA, 6The University of Oklahoma, Oklahoma City, OK, 7GEICO (Grupo Espanol de Investigacion en Cancer de Ovario), Barcelona, Spain, 8Indiana University School of Medicine, Indianapolis, IN, 9University of Arizona Cancer Center, Phoenix, AZ, 10The University of Texas MD Anderson Cancer Center, Houston, TX, 11University of Cincinnati, Cincinnati, OH, 12Memorial Sloan Kettering Cancer Center, New York, NY
